Scynexis (SCYX) Other Non-Current Liabilities (2013 - 2026)
Scynexis (SCYX) posted Other Non-Current Liabilities of $18.9 million for Q1 2026, up 759.09% on a QoQ basis from $2.2 million in Q4 2025, and up 270.59% year-over-year from $5.1 million in Q1 2025.
Scynexis (SCYX) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends
Scynexis' Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $18.9 million for Q1 2026.
- Quarterly Other Non-Current Liabilities rose 270.59% year-over-year to $18.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.9 million (up 270.59% YoY) and the FY2025 annual result came in at $2.2 million, down 72.5% from the prior year.
- Other Non-Current Liabilities was $18.9 million for Q1 2026 at Scynexis, up from $2.2 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $40.3 million in Q1 2023 and bottomed at $2.2 million in Q4 2025.
- A 5-year average of $15.2 million and a median of $12.2 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities soared 5557.86% — and 2025, when it tumbled 83.89%.
- Scynexis' Other Non-Current Liabilities stood at $18.6 million in 2022, then gained by 16.56% to $21.7 million in 2023, then sank by 63.1% to $8.0 million in 2024, then slumped by 72.5% to $2.2 million in 2025, then soared by 759.09% to $18.9 million in 2026.
- Business Quant data shows SCYX's Other Non-Current Liabilities at $18.9 million in Q1 2026, $2.2 million in Q4 2025, and $3.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Scynexis | 21.55 Mn | -15.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.90 Mn |
| Dec 31, 2025 | 2.20 Mn |
| Sep 30, 2025 | 3.54 Mn |
| Jun 30, 2025 | 2.90 Mn |
| Mar 31, 2025 | 5.10 Mn |
| Dec 31, 2024 | 8.00 Mn |
| Sep 30, 2024 | 11.21 Mn |
| Jun 30, 2024 | 18.00 Mn |
| Mar 31, 2024 | 12.20 Mn |
| Dec 31, 2023 | 21.68 Mn |
| Sep 30, 2023 | 24.60 Mn |
| Jun 30, 2023 | 30.09 Mn |
| Mar 31, 2023 | 40.32 Mn |
| Dec 31, 2022 | 18.60 Mn |
| Sep 30, 2022 | 27.73 Mn |
| Jun 30, 2022 | 5.06 Mn |
| Mar 31, 2022 | 7.92 Mn |
| Dec 31, 2021 | 3.35 Mn |
| Sep 30, 2021 | 2.10 Mn |
| Jun 30, 2021 | 24.45 Mn |